18 May 2020 - The EMA's Executive Director Guido Rasi on Monday told a European Parliament committee that the agency could grant conditional marketing authorization to Gilead Sciences’ remdesivir to treat coronavirus disease (COVID-19) in a matter of days.

“It might be that a conditional marketing authorisation can be issued in the coming days, subject to the data that has been submitted,” Rasi said, adding that he does not believe the drug is ready to receive a standard marketing authorisation at this stage.

Read Regulatory Affairs Professional Society article